|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Commissions receivable - current | ||||||||||||||||||||
| Prepaid expense and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Commissions receivable - non-current | ||||||||||||||||||||
| Operating lease ROU asset | ||||||||||||||||||||
| Property, equipment, and capitalized software, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Commissions payable - current | ||||||||||||||||||||
| Short-term operating lease liability | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current liabilities: | ||||||||||||||||||||
| Commissions payable - non-current | ||||||||||||||||||||
| Long-term operating lease liability | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Long-term debt, net of current portion | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Total non-current liabilities | ||||||||||||||||||||
| Series A redeemable convertible preferred stock — $0.0001 par value; 50 shares authorized; 50 shares issued and outstanding as of both March 31, 2026 and December 31, 2025. Liquidation preference of $59.6 million and $58.5 million as of March 31, 2026 and December 31, 2025, respectively. | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Stockholders’ equity (deficit): | ||||||||||||||||||||
| Common stock | ||||||||||||||||||||
| Class A Common Stock | ||||||||||||||||||||
| Class B common stock | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Series A-1 Convertible Preferred Stock | ||||||||||||||||||||
| Total preferred stock | ||||||||||||||||||||
| Treasury stock – at cost; 808 and 793 shares of Class A common stock as of March 31, 2026 and December 31, 2025, respectively. | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity (deficit) attributable to GoHealth, Inc. | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total stockholders’ equity (deficit) | ||||||||||||||||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | ||||||||||||||||||||
Loading...
